Abbott Laboratories (ABT) DIvidends Date & History

Key Takeaways

• ABT offers a current dividend yield of approximately 2.42% with a quarterly payout of $0.63 per share.
• The company maintains a long track record of dividend growth, including 12 consecutive years of increases and membership in the S&P 500 Dividend Aristocrats.
• Dividends are paid quarterly, with the most recent declaration supporting a forward annualized rate near $2.52 per share.
• Payout ratios range from about 48% on forward earnings to higher TTM levels, supported by solid free cash flow coverage around 55%.
• ABT provides moderate yield and growth suited for long-term income and dividend growth investors in the healthcare sector.
• Next ex-dividend date is October 15, 2026, with payment scheduled for November 16, 2026.

Dividend Overview

Abbott Laboratories (ABT) operates as a diversified healthcare company with businesses spanning diagnostics, medical devices, nutrition, and branded generics. The firm pays a quarterly dividend of $0.63 per share, resulting in an annualized rate of approximately $2.52 and a current yield near 2.42% based on recent share prices around $103. This positions ABT as a dividend growth stock rather than a high-yield name, emphasizing consistent increases over elevated income. The policy reflects a commitment to returning capital while funding innovation and acquisitions in a stable sector. Investors receive predictable quarterly payments backed by global operations and recurring revenue streams.

Dividend History and Growth

ABT has paid dividends since 1924, including 411 consecutive quarterly distributions. The company has raised its payout for 54 consecutive years and belongs to the S&P 500 Dividend Aristocrats Index. Recent growth includes 12 straight years of increases, with the annual dividend rising from $1.88 in 2022 to $2.36 in 2025 and further to the current $2.52 annualized level. Compound annual growth rates have averaged 7-10% over multi-year periods. This steady progression demonstrates disciplined capital allocation amid healthcare industry cycles.

Dividend Sustainability and Payout Ratio

The dividend appears sustainable given earnings and free cash flow coverage. Payout ratios stand at approximately 48% on forward earnings and around 55% relative to free cash flow, though trailing twelve-month figures can reach higher levels near 79% depending on reported earnings. Strong operating cash flow exceeding $9 billion annually supports the payout after capital expenditures. Moderate debt levels and diversified revenue reduce risk. Management has reiterated commitment to dividend growth alongside reinvestment needs.

Dividend Compared to Industry Peers

Within healthcare, ABT's yield of roughly 2.42% sits above Johnson & Johnson (around 1.93%) but below peers such as Medtronic (near 3.08%). The profile emphasizes growth and consistency over the highest yields, aligning with medical device and diagnostics firms that balance shareholder returns with research and development spending. This places ABT in the middle of the sector pack for income-focused investors seeking moderate yields with growth potential.

AI Screener

Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify dividend stocks, income-focused investments, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore opportunities with the AI Screener.

Is This Stock Attractive for Dividend Investors?

ABT may appeal to dividend growth investors seeking moderate yields with a history of annual increases and long-term consistency. Conservative, long-term investors could value its healthcare sector stability, recurring revenues, and Dividend Aristocrat status. Income-oriented investors might find the current yield competitive within the industry, though those prioritizing the highest payouts may look elsewhere. The balance of growth, coverage, and sector resilience supports suitability for portfolios focused on sustainable income over multiple market cycles. Investors should assess personal objectives and risk tolerance.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations